Veracyte (VCYT) Cash & Equivalents (2012 - 2026)

Veracyte has reported Cash & Equivalents for 15 years, with the latest figure at $299.5 million in Q2 2026.

• Cash & Equivalents for Q2 2026 came in at $299.5 million, up 36.46% year-over-year; the trailing twelve-month figure through Jun 2026 was $299.5 million (up 36.46% YoY), and the FY2025 annual result was $362.6 million, up 51.65% from the prior year.
• Cash & Equivalents advanced to $299.5 million in Q2 2026, from $263.1 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $362.6 million in Q4 2025 and troughed at $153.4 million in Q2 2022.
• A 5-year average of $224.1 million and a median of $212.8 million in 2023 frame the typical range for Cash & Equivalents.
• The widest annual swing landed in 2022, when Cash & Equivalents tumbled 53.15%; it then soared 51.65% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $154.2 million in 2022, then surged by 40.33% to $216.5 million in 2023, then rose by 10.46% to $239.1 million in 2024, then surged by 51.65% to $362.6 million in 2025, then retreated by 17.39% to $299.5 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $299.5 million in Q2 2026, $263.1 million in Q1 2026, and $362.6 million in Q4 2025.